Loading…
60 Degrees Pharmaceuticals, Inc. is projected to decline to $1.34 by 2027, a -5% move from its current price of $1.41. SXTP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.35 | $1.41 | $1.47 | +0.01% |
| May 30 | $1.33 | $1.41 | $1.50 | +0.01% |
| May 31 | $1.31 | $1.41 | $1.52 | +0.02% |
| Jun 1 | $1.29 | $1.41 | $1.54 | +0.03% |
| Jun 2 | $1.28 | $1.41 | $1.55 | +0.04% |
| Jun 3 | $1.27 | $1.41 | $1.57 | +0.04% |
| Jun 4 | $1.26 | $1.41 | $1.58 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.26 | $1.41 | $1.58 | +0.05% |
| Week 2 | $1.20 | $1.41 | $1.66 | +0.10% |
| Week 3 | $1.16 | $1.41 | $1.72 | +0.15% |
| Week 4 | $1.13 | $1.41 | $1.77 | +0.20% |
| Week 5 | $1.10 | $1.41 | $1.82 | +0.25% |
| Week 6 | $1.07 | $1.41 | $1.87 | +0.30% |
| Week 7 | $1.05 | $1.42 | $1.91 | +0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever.
60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP is a healthcare asset with a current price of $1.48 and a market cap of $3.94M. It is ranked 5396 by market capitalization.
Forecast highlights show a mixed path: in the near term, the average price in 2026 is $1.48 with a range from $1.39 to $1.93 and a neutral sentiment. By 2029 the forecast turns bearish with an average of $1.12 and a max of $1.77 (min $0.764), reflecting a negative ROI of -24.6%. The trajectory improves in the 2030s, turning neutral again with 2030 average $1.29 and max $2.11 (-12.8% ROI), and then becoming bullish in 2033 ($1.84 average, max $3.26, ROI 24.2) and 2034 ($1.80 average, max $3.27, ROI 21.6).
Longer horizon years show stronger upside: 2040 average $2.43 with a max of $4.90 (ROI 64.5) and 2050 average $3.17 with a max of $7.18 (ROI 113.9).
A major floor 27.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.4% away) — a key level to hold.
The nearest ceiling, 39.0% above — a clean break opens room to run.
A major ceiling 268.8% above — clearing it would confirm fresh momentum.
Key SXTP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SXTP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.46 | Sell | $1.45 | Sell |
| MA 10 | $1.45 | Sell | $1.47 | Sell |
| MA 20 | $1.52 | Sell | $1.52 | Sell |
| MA 50 | $1.68 | Sell | $1.80 | Sell |
| MA 100 | $2.38 | Sell | $2.44 | Sell |
| MA 200 | $3.66 | Sell | $5.74 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.23 | Neutral |
| Stoch RSI (14) | 47.21 | Neutral |
| CCI (20) | -95.89 | Neutral |
| Williams %R (14) | -89.47 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -8.44 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 10.53 | Buy |
| TRIX (15) | -0.86 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 44.50 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.48 | Sell |
| ADX (14) | 18.84 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40. The Simple Moving Averages show SMA50 at $1.71 and SMA200 at $3.70.
Support is at $1.39 and resistance at $2.22. The 30-day price range spans from $1.11 to $1.98.
Annualized volatility is listed at 80, reflecting the near-term variability in price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.39 | $1.41 | $1.83 | 0% | Neutral | |
| $1.01 | $1.34 | $1.93 | -5% | Neutral | |
| $0.9711 | $1.36 | $2.05 | -4% | Neutral | |
| $0.7441 | $1.08 | $1.70 | -23% | Bearish | |
| $0.8131 | $1.22 | $1.99 | -13% | Neutral | |
| $1.01 | $1.57 | $2.62 | +11% | Neutral | |
| $1.00 | $1.61 | $2.76 | +14% | Neutral | |
| $1.06 | $1.74 | $3.06 | +23% | Bullish | |
| $1.01 | $1.72 | $3.09 | +22% | Bullish | |
| $0.9108 | $1.58 | $2.91 | +12% | Neutral | |
| $1.18 | $2.34 | $4.66 | +66% | Bullish | |
| $1.37 | $3.03 | $6.79 | +115% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.39 | $1.41 | $1.66 | +0.00% |
| June 2026 | $1.17 | $1.39 | $1.71 | -1.15% |
| July 2026 | $1.18 | $1.42 | $1.78 | +1.83% |
| August 2026 | $1.11 | $1.36 | $1.73 | -4.34% |
| September 2026 | $1.06 | $1.30 | $1.68 | -4.07% |
| October 2026 | $1.10 | $1.36 | $1.77 | +4.15% |
| November 2026 | $1.12 | $1.40 | $1.85 | +3.39% |
| December 2026 | $1.10 | $1.38 | $1.83 | -1.75% |
Click any year to see its month-by-month SXTP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SXTP price prediction for 2026 points to an average of $1.41 (low $1.39, high $1.83) — a potential gain of 0% on today's $1.41. Price action looks broadly range-bound.
In 2027, SXTP is projected to trade between $1.01 and $1.93, averaging $1.34 — a potential decline of -5% from today's $1.41. That is -5% versus the projected 2026 average. A consolidation phase looks the most probable path here.
60 Degrees Pharmaceuticals, Inc.'s 2028 outlook centres on $1.36, within a $0.9711 to $2.05 range. That is up +1% on the projected 2027 average. That marks a -4% change versus current levels. Price action looks broadly range-bound.
By 2029, SXTP could reach as high as $1.70, with a base case around $1.08 and support toward $0.7441 — roughly -23% from $1.41. Expect choppier, lower action through this leg of the cycle.
Expect SXTP to range from $0.8131 to $1.99 through 2030. The $1.22 average target implies a -13% move from current prices. That is up +13% on the projected 2029 average. Price action looks broadly range-bound.
The SXTP price prediction for 2031 points to an average of $1.57 (low $1.01, high $2.62) — a potential gain of +11% on today's $1.41. A consolidation phase looks the most probable path here.
In 2032, SXTP is projected to trade between $1.00 and $2.76, averaging $1.61 — a potential gain of +14% from today's $1.41. That is up +2% on the projected 2031 average. Price action looks broadly range-bound.
60 Degrees Pharmaceuticals, Inc.'s 2033 outlook centres on $1.74, within a $1.06 to $3.06 range. That is up +8% on the projected 2032 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SXTP could reach as high as $3.09, with a base case around $1.72 and support toward $1.01 — roughly +22% from $1.41. Momentum favours further upside here.
Expect SXTP to range from $0.9108 to $2.91 through 2035. The $1.58 average target implies a +12% move from current prices. That is -8% versus the projected 2034 average. A consolidation phase looks the most probable path here.
The SXTP price prediction for 2040 points to an average of $2.34 (low $1.18, high $4.66) — a potential gain of +66% on today's $1.41. Momentum favours further upside here.
In 2050, SXTP is projected to trade between $1.37 and $6.79, averaging $3.03 — a potential gain of +115% from today's $1.41. That is up +30% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SXTP today (≈ 709.219858 SXTP) could be worth
$2,151.36
+$1,151.36 (+115%) by 2050 · US Dollar
Based on the average projected SXTP price of $3.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SXTPwould be worth at today's price.
$1,000 invested in SXTP on May 27, 2025 (≈ 105.932208 SXTP) would be worth
$149.36
-$850.64 (-85.1%) today · 0.15× · US Dollar
Based on a SXTP entry price of $9.44 vs. today's $1.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.4 | $1,007.14 | +0.7% |
| 1 month ago | $1.62 | $870.37 | -13.0% |
| 3 months ago | $2.96 | $476.35 | -52.4% |
| 6 months ago | $4.24 | $332.55 | -66.7% |
| 1 year ago | $9.44 | $149.36 | -85.1% |
| All time (2.9y) ago | $1,123.2 | $1.26 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SXTP forecast.
Our base-case forecast reaches $2.80 around 2050.
Implied market cap at $2.80: $7.45M
Looking at the multi-year forecast, 2026 is seen with min $1.39, avg $1.48, max $1.93 and a NEUTRAL tone. The path includes a notable dip in 2029 with min $0.764, avg $1.12, max $1.77 and ROI -24.6, marked BEARISH.
In 2030 the forecast shows min $0.8519, avg $1.29, max $2.11 with ROI -12.8 and NEUTRAL sentiment. The years 2033 and 2034 turn bullish, with 2033 min $1.10, avg $1.84, max $3.26 (ROI 24.2) and 2034 min $1.05, avg $1.80, max $3.27 (ROI 21.6).
The long-range outlook becomes more positive in 2040, with min $1.21, avg $2.43, max $4.90 and ROI 64.5, sentiment BULLISH. By 2050 the forecast shows further upside: min $1.42, avg $3.17, max $7.18 and ROI 113.9, sentiment BULLISH.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.8519, avg $1.29, max $2.11 with ROI -12.8 and sentiment NEUTRAL.
Forecasts indicate a mixed path: neutral in early years with a Bearish year in 2029, then Neutral to Bullish in later years (2031–2032 Neutral; 2033–2034 Bullish; 2040 and 2050 Bullish). See the year-by-year averages and ROIs: 2026 avg $1.48; 2029 avg $1.12 (ROI -24.6); 2033 avg $1.84 (ROI 24.2); 2040 avg $2.43 (ROI 64.5); 2050 avg $3.17 (ROI 113.9). These figures are estimates and not guarantees.
Yes. The max forecasts exceed $2 in several years: 2033 max $3.26, 2034 max $3.27, 2040 max $4.90, and 2050 max $7.18.
Current price is $1.48 and the rank is 5396.
For 2040 the forecast shows min $1.21, avg $2.43, max $4.90 with ROI 64.5 and sentiment BULLISH.
60 Degrees Pharmaceuticals, Inc. Community Discussion
0Share your 60 Degrees Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.